Publicly funded chemotherapy clinics in NZ have increased 25% in two years, to just over 57,000 outpatient sessions in public hospitals in the 2009/10 year, says Health Minister Tony Ryall. READ MORE>
Archive for the ‘Chemotherapy’ Category
Chemo sessions up 25% in last two years, says NZ Health Minister
Posted in Chemotherapy, tagged catheter, chemotherapy sessions, Health Minister Tony Ryall, NZ cancer treatment stats, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment on October 5, 2010| Leave a Comment »
Viagra combined with chemo drug may be effective prostate cancer treatment
Posted in Chemotherapy, Erectile function, Treatment news, tagged cancer research, catheter, Erectile function, erectile-dysfunction drug Viagra, HEALTH NEWS TODAY, hemotherapy drug, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment on October 5, 2010| 2 Comments »
HEALTH NEWS TODAY: When combined with the erectile-dysfunction drug Viagra, a long-used chemotherapy drug called doxorubicin may be even more effective as a treatment for prostate cancer, according to a new study. READ MORE>
New chemo drug for advanced prostate cancer approved by FDA
Posted in Chemotherapy, New prostate drugs, PROSTATE CANCER, tagged advanced prostate cancer, cancer research, catheter, chemotherapy drug, Jevtana, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, steroid prednisone, U.S. Food and Drug Administration, WALL ST JOURNAL on June 20, 2010| Leave a Comment »
WALL ST JOURNAL: The US Food and Drug Administration has approved Jevtana, a chemotherapy drug used in combination with the steroid prednisone to treat men with advanced prostate cancer. READ MORE> and HERE>
Abiraterone acetate: A promising drug for the treatment of castration-resistant prostate cancer
Posted in Chemotherapy, Hormone therapy, Hormone-refactory, PROSTATE CANCER, Prostate drugs, PROSTATE RESEARCH, tagged abiraterone acetate, advanced prostate cancer, cancer research, castration, castration-resistant disease, catheter, Chemotherapy, Hormone therapy, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment debate, URO TODAY on May 29, 2010| 1 Comment »
URO TODAY: Abiraterone acetate is a promising treatment for advanced prostate cancer patients and is being tested in a Phase III trial for men with progressive castration-resistant prostate cancer who have not had chemotherapy.
A Phase III trial for patients following prior chemotherapy has been completed and is awaiting analysis. READ MORE>
Expert panel says how prostate cancer treatments could be improved
Posted in Brachytherapy, Chemotherapy, Erectile function, Hormone therapy, Incontinence, PROSTATE CANCER, PROSTATE RESEARCH, Radical prostatectomy, Radiotherapy, tagged cancer research, catheter, comparison of treatments, Incontinence, National Library of Medicine PubMed, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, URO TODAY on May 29, 2010| 1 Comment »
URO TODAY: The five main prostate cancer treatments can all have bad side effects, so a panel of 15 specialists have compared them and come up with some recommended improvements.
Prostate cancer (PC) is one of the tumours with the highest incidence in recent years. PC therapies have several adverse effects.
A panel consensus recommendation has been made to prevent or ameliorate complications in PC treatment to improve quality of life.
Fifteen specialists have met to analyse the different toxicities associated with PC treatment.
Each medical specialist searched National Library of Medicine PubMed citations about these secondary effects and his specialty from 1999 to 2009 to propose measures for their prevention/amelioration.
- Surgery is associated with incontinence and impotence.
- Radiotherapy can produce acute, late urological and gastrointestinal toxicity.
- Brachytherapy can produce acute urinary retention.
- Chemotherapy is associated with haematotoxicity. peripheral neuropathy and diarrhoea.
- And hormone therapy can produce osteoporosis, metabolic syndrome, cognitive and muscular alterations, cardiotoxicity, etc.
Improvement in surgical techniques and technology (IMRT/IGRT) can prevent surgical and radiotherapeutic toxicity, respectively.
Brachytherapy toxicity can be prevented with precise techniques to preserve the urethra.
Chemotherapy toxicity can be prevented with personalized schedules of treatment and close follow-up of iatrogenia
And hormone therapy toxicity can be prevented with close follow-up of possible secondary effects.
Benefit seen in having chemo-radiation treatment prior to prostate removal
Posted in Chemotherapy, PROSTATE CANCER, PROSTATE RESEARCH, Radical prostatectomy, Radiotherapy, tagged combination of radiation therapy and chemotherapy, improve patient survival, prostablog, prostate, prostate blog, prostate cancer treatments, prostate removal, prostate treatment, Radical prostatectomy, Radiotherapy, reduce cancer recurrence, Science Daily on November 6, 2009| Leave a Comment »
SCIENCE DAILY: A combination of radiation therapy and chemotherapy given before prostate removal is safe and may have the potential to reduce cancer recurrence and improve patient survival. READ MORE>
Experiment with chemo combination works for hormone refractory prostate cancer patients
Posted in Chemotherapy, Hormone-refactory, PROSTATE CANCER, PROSTATE RESEARCH, PSA tests, Treatment news, tagged advanced prostate cancer, cancer research, Chemotherapy, docetaxel/zoledronic/prednisone, Gleason score, hormone-refractory, Indian researchers, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, significantly better survival, URO TODAY on October 29, 2009| 1 Comment »
URO TODAY: A combination of docetaxel/zoledronic/prednisone in chemotherapy for hormone refractory prostate cancer patients is safe and effective, say Indian researchers. For patients with a Gleason score less than 7, PSA declined more than 50% and those who received more than four cycles had significantly better survival. READ MORE>
Researchers discover way to manipulate a gene product so cancer cells die
Posted in Chemotherapy, Gene therapy, PROSTATE CANCER, PROSTATE RESEARCH, tagged cancer research, cancer treatment, cause cancer cells to die, Chemotherapy, manipulate a gene product, MEDICAL NEWS TODAY, prostablog, prostate blog, prostate treatment, prostate treatment debate, University of New Jersey on October 28, 2009| Leave a Comment »
MEDICAL NEWS TODAY: In trying to better predict a patient’s response to chemotherapy, a team of investigators at the State University of New Jersey has identified a way to better manipulate a gene product to cause cancer cells to die. READ MORE>
Trial begins on new antagonist drug that takes over after docetaxel-based chemotherapy
Posted in Chemotherapy, Hormone-refactory, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news, tagged advanced prostate cancer, AFFIRM, cancer research, castration-resistant prostate cancer, docetaxel-based chemotherapy, drug MDV3100, MEDICAL NEWS TODAY, novel androgen receptor antagonist, phase 3 clinical trial, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate on September 25, 2009| Leave a Comment »
MEDICAL NEWS TODAY: A phase 3 clinical trial of the investigational drug MDV3100 for advanced prostate cancer has just begun in the US. READ MORE>
Known as AFFIRM, the trial will evaluate the novel androgen receptor antagonist MDV3100 in men with castration-resistant prostate cancer who were previously treated with .
Looking at why many advanced prostate cancer patients have PSA surge during chemotherapy
Posted in Chemotherapy, PROSTATE CANCER, PROSTATE RESEARCH, PSA tests, Treatment news, tagged advanced prostate cancer, cancer research, castration-refractory prostate cancer patients, Chemotherapy, initial PSA surge/flare-up, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, Texas prostate scientists, URO TODAY on September 18, 2009| Leave a Comment »
URO TODAY: Scientists in Texas have been analysing data on the considerable number of castration-refractory prostate cancer patients who experience an initial PSA surge/flare-up while having chemotherapy. READ MORE>